Home › Uveal Melanoma › Ohio › Columbus
Uveal Melanoma clinical trials in Columbus, OH
5 studies for Uveal Melanoma are looking for participants at sites in and around Columbus (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RecruitingPhase 2
- The Ohio State University, Columbus
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RecruitingPhase 1/2
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RecruitingPhase 3
- Ohio State Eye and Ear Institute, Columbus
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingPhase 2/3
- The Ohio State University, Columbus
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
RecruitingObservational studyHealthy volunteers welcome
- The Ohio State University Wexner Medical Center, Columbus
Uveal Melanoma trials in other cities
- Philadelphia, PA7 studies
- Los Angeles, CA6 studies
- Nashville, TN6 studies
- New York City, NY5 studies
- Boston, MA5 studies
- Houston, TX5 studies
- Scottsdale, AZ5 studies
- Denver, CO5 studies
- Miami, FL4 studies
- Tampa, FL4 studies
- Mountain View, CA4 studies
- Aurora, CO4 studies
Other studies in Columbus
- Non-Small Cell Lung Cancer56 studies
- Breast Cancer39 studies
- Ovarian Cancer39 studies
- Cancer (all types)38 studies
- Lung Cancer37 studies
- Acute Myeloid Leukemia35 studies
- Chronic Lymphocytic Leukemia28 studies
- Metastatic Cancer27 studies
- Endometrial Cancer25 studies
- Colorectal Cancer24 studies
- Prostate Cancer24 studies
- Multiple Myeloma24 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.